OSR HEALTH INC
OSRHNASDAQTrading Snapshot
- Day Range
- $0.12 – $0.12
- 52-Week Range
- $0.08 – $0.91
- Volume
- $2.84B
- Avg Volume
- $3.17B
- Shares Outstanding
- 33.1M
- Next Earnings
- Oct 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $315,669
- P/E Ratio
- -0.0
- P/S Ratio
- 2.1x
- EPS (TTM)
- $-3.38
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.0%
Why Investors Own OSRH
- ✓High-growth profile — revenue up +49.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 29% gross margin and 4% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
OSR HEALTH INC
OSRH
StockOtter · stockotter.spaceAbout OSR HEALTH INC
OSR Holdings, Inc. operates as a Special Purpose Acquisition Company (SPAC) – essentially a blank check entity. Its primary objective is to execute a substantial business combination, which may take the form of a merger, a capital stock exchange, an asset acquisition, a stock purchase, a reorganization, or other comparable strategic transaction with one or more established businesses. The company was incorporated on February 25, 2020, and maintains its principal office in Bellevue, Washington.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc.
NEW YORK CITY, NY / ACCESS Newswire / August 27, 2026 / Emerging Growth Research, LLC ("Emerging Growth Research" or "EGR") today announced the release of its company-sponsored research flash report on OSR Health, Inc. (
OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission
The Company details its Nasdaq hearing request, its $15 million Put Option, and continued development across its subsidiary pipeline BELLEVUE, WA / ACCESS Newswire / August 21, 2026 / OSR Health, Inc. (NASDAQ:OSRH) tod
OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that it has received a written Staff Delisting Determination (the "Determination") from th
OSR Health Sees Global Shareholder Momentum at Critical Inflection Point
Company cites extraordinary trading activity, global shareholder support, and continued commitment to Nasdaq compliance and the CVR program. BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSR
OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development
Founder and CEO addresses the Company's Nasdaq listing status and accelerating subsidiary business development BELLEVUE, WA / ACCESS Newswire / August 11, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the followin
OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program
BELLEVUE, WA / ACCESS Newswire / August 7, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today issued a clarification regarding its press release dated July 31, 2026 concerning the Nasdaq Stock Ma